Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13913061 | 0.85 | KDM4E (0.67) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL14023220 | 0.71 | KDM4E (0.61) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL918303 | 0.71 | TDP1 (0.51) | CYP1A2CYP2D6CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL2284215 | 0.70 | TDP1 (0.50) | MEN1KMT2ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3670226 | 0.70 | TDP1 (0.50) | MEN1KMT2ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL13765228 | 0.69 | APP (0.39) | CYP2C19 | |
| SCHEMBL14369320 | 0.69 | PTPN1 (0.30) | — | |
| SCHEMBL2169798 | 0.67 | TDP1 (0.54) | ACHE | |
| SCHEMBL21867108 | 0.67 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2AHSD17B10MAPK1 | |
| SCHEMBL24813700 | 0.67 | STAT3 (0.57) | KDM4EALDH1A1MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | NGF, BDNF, NTRK2 | KDM4E 4479/4885ALDH1A1 2086/4885MEN1 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.